Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kei Irie

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|September 6, 2019
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case reportAtsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, et al.
JTO Clinical and Research Reports|September 30, 2021
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With <i>MET</i> Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case ReportTaira Ninomaru, Hideaki Okada, Mika Fujishima, et al.
Journal of Clinical Pharmacology|August 12, 2025
From PICU to NICU: Extrapolating Meropenem Exposure From Pediatric to Neonatal Intensive Care PatientsRonaldo Morales Junior, Tomoyuki Mizuno, Wen Rui Tan, et al.
Urologic Oncology|September 29, 2020
Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancerRieko Miura, Masaki Hirabatake, Kei Irie, et al.
Bioanalysis|May 16, 2019
Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluidKei Irie, Shigeki Nanjo, Akito Hata, et al.
Thoracic Cancer|June 26, 2024
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinibYuki Sato, Yoshiharu Sato, Kei Irie, et al.
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Biomaterials|June 25, 2011
Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cellsYuriko Higuchi, Can Wu, Kai-Ling Chang, et al.
Oncology|June 15, 2018
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsKatsuhiro Masago, Kei Irie, Shiro Fujita, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|September 6, 2019
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case reportAtsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, et al.
JTO Clinical and Research Reports|September 30, 2021
Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With <i>MET</i> Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case ReportTaira Ninomaru, Hideaki Okada, Mika Fujishima, et al.
Journal of Clinical Pharmacology|August 12, 2025
From PICU to NICU: Extrapolating Meropenem Exposure From Pediatric to Neonatal Intensive Care PatientsRonaldo Morales Junior, Tomoyuki Mizuno, Wen Rui Tan, et al.
Urologic Oncology|September 29, 2020
Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancerRieko Miura, Masaki Hirabatake, Kei Irie, et al.
Bioanalysis|May 16, 2019
Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluidKei Irie, Shigeki Nanjo, Akito Hata, et al.
Thoracic Cancer|June 26, 2024
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinibYuki Sato, Yoshiharu Sato, Kei Irie, et al.
Clinical and Translational Science|February 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's diseaseAbigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Biomaterials|June 25, 2011
Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cellsYuriko Higuchi, Can Wu, Kai-Ling Chang, et al.
Oncology|June 15, 2018
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsKatsuhiro Masago, Kei Irie, Shiro Fujita, et al.
Clinical Pharmacokinetics|August 30, 2025
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's DiseaseKei Irie, Phillip Minar, Jack Reifenberg, et al.
Pageof 6